摘要
目的观察恩度（重组人血管内皮抑素,YH-16）联合同步化疗、放疗方案治疗局部晚期非小细胞肺癌（NSCLC）的近期临床效果和安全性。方法回顾性分析2010年2月~2012年12月武汉大学人民医院肿瘤内科经病理组织学确诊59例局部晚期NSCLC患者的临床资料。依纳入标准,分为30例恩度联合同步放化疗组（试验组）和29例同步放化疗组（对照组）,以客观有效率（RR,CR＋PR）、临床获益率（CBR）、1年生存率和1年无进展生存率为近期疗效评价指标。评价血液学毒性、消化道反应、心脏毒性、放射性肺炎和放射性食管炎等毒副反应。结果试验组与对照组的RR和CR＋PR分别为66.7%、37.9%,CBR分别为90%、69%,两组的RR和CBR比较差异有统计学意义（P〈0.05）,1年生存率分别为70.0%、51.7%,1年无进展生存率分别为56.6%、44.8%,差异无统计学意义（P〉0.05）。主要的不良反应有骨髓抑制、恶心呕吐、心脏毒性、急性放射性肺炎及食管炎,两组不良反应比较差异均无统计学意义（P〉0.05）。结论同步放化疗联合恩度治疗晚期NSCLC的临床治疗近期疗效好,其毒副反应可以耐受。
Objective To evaluate the recent clinical efficacy and safety of Endostar（YH-16） combined with concurrent chemotherapy and radiotherapy in the treatment of locally advanced non-small cell lung cancer（NSCLC）. Methods Clinical data of 59 patients confirmed by Department of Oncology in Renmin Hospital of Wuhan University with locally advanced NSCLC from February 2010 to December 2012 were analyzed retrospectively. According to the inclusion criteria, 30 cases of them were treated by endostar plus chemoradiotherapy（trial group）, 29 cases of them were treated by chemoradio therapy（control group）. The response rate（RR, CR＋PR）, clinical benefit rate（CBR）, 1-year overall survival rate and 1-year progression free survival rate were evaluated for the short-term efficacy. The hematological toxicity, cardiactoxicity, gastrointestinal and radiation reactions were evaluated. Results The response rates were66.7% and 37.9% in trial group and control group respectively. The clinical benefit rates of the trial group and control group was 90%and 69% respectively. The difference of these two groups in RR and CBR were statistically significant（P〈0.05）. The 1-year overall survival rate and 1-year progression free survival rate in trial group and control group were 70.0% vs 51.7% and 56.6% vs 44.8% respectively, without significant difference（P〈0.05）. The difference of main adverse reactions including gastrointestinal and radiation reactions, hematological toxicity, cardiactoxicity, acute radiation pneumonitis and acute radiation esophagitis between two groups were not statistically significant（P〈0.05）. Conclusion Endostar combined with concurrent chemoradio therapy can improve the short-term efficacy for advanced NSCLC and its toxicity can be tolerated.
出处
《中国医药导报》
CAS
2016年第14期84-87,共4页
China Medical Herald
基金
国家自然科学基金资助项目(30970860)
关键词
非小细胞肺癌
恩度
同步放化疗
不良反应
Non-small cell lung cancer
Endostatin/ endostar
Concurrent chemoradiotherapy
Adverse reaction
